XML 28 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
Debt Financing (Tables)
9 Months Ended
Sep. 30, 2012
Debt Financing [Abstract]  
Convertible notes, loans and contingent liabilities
The details of the convertible notes, loans and contingent liabilities are as follows at September 30, 2012:
 
Lender
 
1st-Issue
Date
 
 
Principal
Amount
 
 
Duration
(Note)
 
Interest
Rate
 
Conversion
 Price
(stated)
 
 
Fixed
EUR/USD
 Rate for
Conversion
Price
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Norwood Secured Loan
 
04/03/2009
 
 
E
2,500
 
 
 
(5
)
5% pa
 
$
US 0.50
 
 
 
1.2812
 
Eardley Holding A.G. (1)
 
06/23/2006
 
 
E
148
 
 
 
(2
)
10% pa
 
$
US 0.10
 
 
 
N/A
 
Anglo Irish Bank S.A. (3)
 
10/21/2007
 
 
E
500
 
 
 
(2
)
10% pa
 
$
US 0.50
 
 
 
1.4090
 
Round Enterprises Ltd.
 
12/10/2007
 
 
E
1,500
 
 
 
(2
)
10% pa
 
$
US 0.50
 
 
 
1.4429
 
Round Enterprises Ltd.
 
01/22/2008
 
 
E
1,500
 
 
 
(2
)
10% pa
 
$
US 0.50
 
 
 
1.4629
 
Round Enterprises Ltd.
 
04/25/2008
 
 
E
2,000
 
 
 
(2
)
10% pa
 
$
US 0.50
 
 
 
1.5889
 
Round Enterprises Ltd.
 
06/30/2008
 
 
E
1,500
 
 
 
(2
)
10% pa
 
$
US 0.50
 
 
 
1.5380
 
Round Enterprises Ltd.
 
11/18/2008
 
 
E
1,200
 
 
 
(2
)
10% pa
 
$
US 0.50
 
 
 
1.2650
 
Round Enterprises Ltd.
 
02/09/2009
 
 
E
1,500
 
 
 
(2
)
10% pa
 
$
US 0.50
 
 
 
1.2940
 
Round Enterprises Ltd.
 
06/15/2009
 
 
E
5,500
 
 
 
(2,4
)
10% pa
 
$
US 0.80
 
 
 
1.4045
 
Eardley Holding A.G.
 
06/15/2009
 
 
E
100
 
 
 
(2,4
)
10% pa
 
$
US 0.80
 
 
 
1.4300
 
Von Meyenburg
 
08/03/2009
 
 
E
200
 
 
 
(2
)
10% pa
 
$
US 0.80
 
 
 
1.4400
 
Round Enterprises Ltd.
 
10/13/2009
 
 
E
2,000
 
 
 
(2
)
5% pa
 
$
US 0.25
 
 
 
1.4854
 
Round Enterprises Ltd.
 
12/18/2009
 
 
E
2,200
 
 
 
(2
)
5% pa
 
$
US 0.25
 
 
 
1.4338
 
Round Enterprises Ltd.
 
08/04/2011
 
 
E
933
 
 
 
(7
)
10% pa
 
None(4)
 
 
 
N/A
 
Eardley Holding A.G.
 
08/04/2011
 
 
E
233
 
 
 
(7
)
10% pa
 
None(4)
 
 
 
N/A
 
Round Enterprises Ltd.
 
11/08/2011
 
 
E
400
 
 
 
(8
)
10% pa
 
None(4)
 
 
 
N/A
 
Eardley Holding A.G.
 
11/08/2011
 
 
E
100
 
 
 
(8
)
10% pa
 
None(4)
 
 
 
N/A
 
Round Enterprises Ltd.
 
02/17/2012
 
 
E
1,000
 
 
 
(8
)
10% pa
 
None(4)
 
 
 
N/A
 
Eardley Holding A.G.
 
02/17/2012
 
 
E
200
 
 
 
(8
)
10% pa
 
None(4)
 
 
 
N/A
 
Round Enterprises Ltd.
 
04/19/2012
 
 
E
322
 
 
 
(8
)
10% pa
 
None(4)
 
 
 
N/A
 
Eardley Holding A.G.
 
04/19/2012
 
 
E
80
 
 
 
(8
)
10% pa
 
None(4)
 
 
 
N/A
 
Round Enterprises Ltd.
 
05/04/2012
 
 
E
480
 
 
 
(8
)
10% pa
 
None(4)
 
 
 
N/A
 
Eardley Holding A.G.
 
05/04/2012
 
 
E
120
 
 
 
(8
)
10% pa
 
None(4)
 
 
 
N/A
 
Round Enterprises Ltd.
 
09/03/2012
 
 
E
200
 
 
 
(8
)
10% pa
 
None(4)
 
 
 
N/A
 
Eardley Holding A.G.
 
09/03/2012
 
 
E
50
 
 
 
(8
)
10% pa
 
None(4)
 
 
 
N/A
 
Total Short Term Principal Amounts
 
 
 
 
E
26,466
 
 
 
 
 
 
 
 
 
 
 
 
 
Accrued Interest
 
 
 
 
E
7,171
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Convertible Notes to Related Parties
 
 
 
 
E
33,637
 
 
 
 
 
 
 
 
 
 
 
 
 
Norwood Contingent Liability
 
 
 
 
E
6,323
 
 
 
(6
)
 
 
 
 
 
 
 
 
TOTAL LOANS, NOTES,AND CONTINGENT LIABILITY
 
 
 
E
39,960
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) Private investment company of Dr. Thomas Staehelin, member of the Board of Directors and of the Audit Committee of the Company. Face value is stated in U.S. dollars at $190.

(2) The loans expire the earlier of (i) November 30, 2012 or (ii) upon an event of default. The loans are secured by the IP assets of the Company.

(3) Renamed Hyposwiss Private Bank Geneve S.A. and acting on behalf of Round Enterprises Ltd. which is a major shareholder.

(4) The loans expire the earlier of (i) November 30, 2012 or (ii) upon an event of default. The loan is secured against 2/3rds of the IP assets of Bestewil Holding BV.

(5) Under the terms of the acquisition of Bestewil BV, as part of the consideration, the Company issued to Norwood Immunology Limited ("NIL") a convertible redeemable note (the "Note") in the principal amount of E2,500 with a maturity date of April 1st, 2012 and bearing interest at 5% per annum. The note is secured against 1/3rd of Bestewil common stock. On April 19, 2012, Mymetics and (NIL) agreed to an amendment to the E2,500 loan agreement. The amended agreement resulted in the payment E402 on April 20, 2012 covering all the accrued interest due to NIL and a delay of the repayment of the E2,500 loan until September 30, 2012, with a 5% interest per annum starting April 20, 2012. The repayment of the loan will be half in shares and half in cash and is contingent on an investment in the Company of not less than $20,000 by new investors. The conversion price is determined by reducing by 10% the price per share of the Company's common stock paid by the investors in connection with such an investment. In the event Mymetics is not able to close the investment of not less than $20,000 from new investors on or before September 30, 2012, the loan and accrued interest become immediately payable. On October 31, 2012, Mymetics agreed with NIL to amend the terms and conditions of the second amendment signed on September 21, 2012. The deadline of October 31, 2012 for Mymetics to close the investment has been moved to December 31, 2012. The interest rate of the loan has changed from 5% to 10% starting from November 1, 2012 and Mymetics will pay E109 to NIL by November 16, 2012, which reflects the interest on the loan until December 31, 2012.
 
(6) Under the terms of the acquisition of Bestewil BV, as part of the consideration, the Company is committed to make further payments to NIL in the event that certain stated milestones for the development of vaccines are achieved. These have been considered on a risk probability basis.

(7) The loans expire the earlier of (i) November 30, 2012 or (ii) upon an event of default. The face values of the loans are stated in U.S. dollars at $1,200 and $300, respectively. These notes are under negotiation as they are expiring.

(8) The loans expire the earlier of (i) November 30, 2012 or (ii) upon an event of default.
 
Schedule of future payments of long term debt
Required future payments on long-term debt are as follows as of September 30, 2012:

2012
 
E
33,637
 
Contingent liability to Norwood (milestones and royalties)
 
E
6,323
 
 
 
E
39,960